Oatmeal Health

Oatmeal Health

An AI platform that finds lung cancer screening candidates for community health centers

Officially listed
English
Paid
医疗AI工具
0favorites
1views
Promote this tool
Oatmeal Health screenshot

Tool details

Only about 18% of Americans who qualify for lung cancer screening actually get screened. Oatmeal Health stitches three jobs into one pipeline — finding who qualifies, calling them in, and adding a second read on the scan — for community health centers and imaging networks.

Core Capabilities

  • LungIQ finds patients: reads progress notes, diagnoses and prescriptions, pulls smoking history out of free text, and returns a ranked candidate list with the reason each patient was flagged.
  • LungNAV reaches them: AI voice calls explain low-dose CT in plain language, prepare patients for the shared decision-making visit, then hand a call summary to the scheduling team.
  • LungAI scores nodules: gives every nodule a malignancy risk score from 0 to 100, shown inside the viewer radiologists already use.
  • No workflow change: no new workstation, no new login, no new IT project — one PDF report per exam goes back to PACS.
  • Evidence stance: on held-out NLST data, LungAI reached 0.92 AUROC for malignancy discrimination.
  • Free tooling: pack-year calculator, county-level radon maps and reimbursement guides, all public.

Use Cases Federally qualified health centers, hospitals and imaging networks, health plans, and pharma or device companies that need diverse patient populations. Customers are institutions rather than individuals, and engagements are partnerships rather than self-serve signups.

What Sets It Apart Most competitors only cover the reading step. Oatmeal goes from "who should be screened" all the way to "who actually showed up"; at an external validation site LungIQ reached 0.96 AUROC and 94% of the top 100 ranked patients were confirmed eligible. That chain is the hardest part to copy.

Editor's Take One thing must be said plainly: LungAI is still investigational, not FDA cleared, and cannot be sold in the United States. The value today sits in LungIQ, which fixes the dullest and deadliest link in the screening chain. Founded in 2022 on a small budget yet with a six-year distribution deal signed, the execution deserves attention.

Pricing

Custom pricingBilled per scan (about $650 per scan, CPT 0721T)
LungIQ patient identification
Custom (institutional quote)

Quoted by patient panel size and programme scope

LungNAV outreach module
Custom (add-on)

Optional add-on to LungIQ, includes multilingual calls

LungAI reading support
Custom (per scan)

Billed per scan after clearance; not commercially available today

Additional notes

No public price list; everything runs through partnership discussions. The founder's framing is per-scan billing under CPT 0721T. LungAI is not FDA cleared and cannot be sold in the United States.

FAQ

It does not charge individuals and offers no self-serve signup. Pricing is set per institutional partnership with no public list price; the commercial framing is per-scan billing at about $650 per scan.

User reviews

User Reviews

No reviews yet

No one has reviewed this tool yet